FEMY News and Press, Femasys Inc. From 03/06/24

-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Court Ruling creates continued anticipation with top-line pivotal data expected to be anno...

-- Femasys readies for the commercial launch of FemaSeed ® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) -- -- Femasys to announce top-line data from recently completed pivota...

2024-02-12 10:00:07 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 7.9% to $23.6 on volume of 254,911,069 shares MicroCloud Hologram Inc. (HOLO) rose 1092.1% to $18 on volume of 194,069,467 shares Snap Inc. Class A (SNAP) fell 34.6% to $11.41 on volume o...

-- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedica...

UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in the FemBloc pivotal trial since enrollment began last quarter - UC Davis Professor of the Obstetrics and Gynecology (OB/GYN) Department and Director of the Comple...

- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys’ earlier FemBloc study - - FemBloc is being developed as a first-of-its-kind, non-surgical permanent birth control with a clear U.S. re...

2024-01-19 14:26:07 ET (24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) reported, this morning, that the FDA approved... For further details see: FDA Approves IDE for the Pivotal Clinical Trial of Femasys’ FemBloc Permanent Birth Control

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last quarter - - Faculty of the Stanford Medicine Obstetrics and Gyneco...

2023-11-30 17:40:37 ET More on Femasys Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner Femasys regains Nasdaq compliance Financial information for Femasys For further details see: Femasys filed to sell 18.11M shares of common st...